{
    "clinical_study": {
        "@rank": "33542", 
        "acronym": "MOVE", 
        "arm_group": [
            {
                "arm_group_label": "Treatment sequence I", 
                "arm_group_type": "Active Comparator", 
                "description": "QVA149 once a day during 21 days cross-over to placebo once a day for up to 21 days"
            }, 
            {
                "arm_group_label": "Treatment sequence II", 
                "arm_group_type": "Active Comparator", 
                "description": "Placebo once a day during 21 days cross-over to QVA149 once a day for 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on\n      pulmonary function and average physical activity levels in patients with moderate to severe\n      Chronic Obstructive Pulmonary Disease (COPD)."
        }, 
        "brief_title": "Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with stable COPD according to the current GOLD guidelines (GOLD 2013). Current or\n        ex-smokers who have a smoking history of at least 10 pack years (e.g. 10 pack years = 1\n        pack /day x 10 yrs, or \u00bd pack/day x 20 yrs)..\n\n        Patients with airflow limitation indicated by a post-bronchodilator FEV1 \u226540% and <80% of\n        the predicted normal, and a post-bronchodilator FEV1/FVC <0.70\n\n        Exclusion Criteria:\n\n        Patients with conditions contraindicated for treatment with, or having a history of\n        reactions/hypersensitivity to any of the following inhaled drugs, drugs of a similar class\n        or any component thereof, anticholinergics, long and short acting beta2 agonists,\n        sympathomimetic amines, lactose or any of the other excipients Patients who have a\n        clinically significant ECG abnormality at Visit 1, who in the judgment of the investigator\n        would be at potential risk if enrolled into the study.\n\n        Patients with paroxysmal (e.g. intermittent) atrial fibrillation are excluded. Patients\n        with persistent atrial fibrillation as defined by continuous atrial fibrillation for at\n        least 6 months and controlled with a rate control strategy (i.e., beta blocker, calcium\n        channel blocker, pacemaker placement, digoxin or ablation therapy) for at least 6 months\n        may be considered for inclusion. In such patients, atrial fibrillation must be present at\n        baseline and screening visits, with a resting ventricular rate < 100/min.\n\n        Patients with Type I or uncontrolled Type II diabetes and patients with a history of blood\n        glucose levels consistently outside the normal range Patients with narrow-angle glaucoma,\n        symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal\n        impairment or urinary retention.\n\n        Patients with a history of malignancy of any organ system, treated or untreated, within\n        the past 5 years whether or not there is evidence of local recurrence or metastases, with\n        the exception of localized basal cell carcinoma of the skin. Patients with non-melanoma\n        skin carcinoma may be considered for the study.\n\n        Patients with a body mass index (BMI) of more than 40 kg/m2. Women who are pregnant or\n        breast feeding Patients requiring long term oxygen therapy on a daily basis for chronic\n        hypoxemia.\n\n        Patients who have had a COPD exacerbation that required treatment with antibiotics and/or\n        oral corticosteroids and/or hospitalization in the 6 weeks prior to screening.\n\n        Patients who have had a respiratory tract infection within 4 weeks prior to screening.\n\n        Patients with any history of asthma. Patients with concomitant pulmonary disease Patients\n        with clinically significant bronchiectasis. Other protocol-defined inclusion/exclusion\n        criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996319", 
            "org_study_id": "CQVA149ADE03"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment sequence I", 
                    "Treatment sequence II"
                ], 
                "description": "QVA149 (110/50 \u00b5g) once a day via Breezhaler\u00ae device", 
                "intervention_name": "QVA149", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment sequence I", 
                    "Treatment sequence II"
                ], 
                "description": "Placebo once a day via Breezhaler\u00ae device", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic obstructive pulmonary disease", 
            "COPD"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Koblenz", 
                        "country": "Germany", 
                        "state": "NRW", 
                        "zip": "56068"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cottbus", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "03050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aschaffenburg", 
                        "country": "Germany", 
                        "zip": "63739"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12203"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dueren", 
                        "country": "Germany", 
                        "zip": "52349"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "zip": "91052"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Euskirchen", 
                        "country": "Germany", 
                        "zip": "53879"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Geesthacht", 
                        "country": "Germany", 
                        "zip": "22502"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grosshansdorf", 
                        "country": "Germany", 
                        "zip": "22947"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69117"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "H\u00f6chstadt", 
                        "country": "Germany", 
                        "zip": "91315"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koeln", 
                        "country": "Germany", 
                        "zip": "50672"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "51605"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04103"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04207"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L\u00fcbeck", 
                        "country": "Germany", 
                        "zip": "23558"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marburg", 
                        "country": "Germany", 
                        "zip": "35037"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnster", 
                        "country": "Germany", 
                        "zip": "48145"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neunkirchen", 
                        "country": "Germany", 
                        "zip": "66539"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Potsdam", 
                        "country": "Germany", 
                        "zip": "14469"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Potsdam", 
                        "country": "Germany", 
                        "zip": "14467"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rheine", 
                        "country": "Germany", 
                        "zip": "48431"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "R\u00fcdersdorf", 
                        "country": "Germany", 
                        "zip": "15562"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saarbruecken", 
                        "country": "Germany", 
                        "zip": "66111"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Teterow", 
                        "country": "Germany", 
                        "zip": "17166"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wedel", 
                        "country": "Germany", 
                        "zip": "22880"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiesloch", 
                        "country": "Germany", 
                        "zip": "69168"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "MOVE - A Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Inspiratory capacity (IC) will be measured with spirometry conducted according to internationally accepted standards. The mean of 3 acceptable measurements will be calculated and reported in liters.", 
                "measure": "Peak inspiratory capacity (IC) comparison between QVA149 and Placebo", 
                "safety_issue": "No", 
                "time_frame": "Baseline and day 21"
            }, 
            {
                "description": "Average physical activity level is defined by average daily activity-related energy consumption [Kcal/day], measured via Actinography device.", 
                "measure": "Comparison of QVA149 versus placebo with respect to average physical activity level", 
                "safety_issue": "No", 
                "time_frame": "Baseline, day 15, baseline day 35, day 56"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996319"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The average number of steps per day will be measured via Actinography device.", 
                "measure": "Comparison of QVA149 vs. placebo on the average number of steps per day", 
                "safety_issue": "No", 
                "time_frame": "Baseline, day 15, baseline day 35, day 56"
            }, 
            {
                "description": "Least moderate activity (defined as 3,5-7kcal/min) will be measured via Actinography device.", 
                "measure": "Comparison of QVA149 versus placebo on the duration of at least moderate activity per day", 
                "safety_issue": "No", 
                "time_frame": "Baseline, day 15, baseline day 35, day 56"
            }, 
            {
                "description": "Inspiratory capacity (IC) will be measured with spirometry conducted according to internationally accepted standards. The mean of 3 acceptable measurements will be calculated and reported in liters.", 
                "measure": "Peak IC comparison between QVA149 and Placebo.", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Inspiratory capacity (IC) will be measured with spirometry conducted according to internationally accepted standards. The mean of 3 acceptable measurements will be calculated and reported in liters.", 
                "measure": "Trough IC comparison between QVA149 and Placebo", 
                "safety_issue": "No", 
                "time_frame": "Day 20"
            }, 
            {
                "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.", 
                "measure": "Peak forced expiratory volume 1 (FEV1) comparison between QVA149 and Placebo", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.", 
                "measure": "Trough FEV1 comparison between QVA149 and placebo", 
                "safety_issue": "No", 
                "time_frame": "Day 20"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}